40 results about "Stromal tumor" patented technology

The present invention relates to a method for the ex vivo molecular diagnosis of gastrointestinal stromal tumors, comprising the steps of: providing at least one isolated tissue sample comprising at least one nucleic acid and the subsequent extraction of the at least one nucleic acid. The method according to the present invention further comprises a step of quantifying the at least one previously isolated nucleic acid. Furthermore, the method according to the present invention comprises preparing at least one amplicon library of said previously isolated nucleic acid, which comprises sequences obtained from the FGFR1, NF1, SDHA, SDHB, SDHC and SDHD genes. This step is followed by the step of purifying the at least one amplicon library and the step of simultaneously sequencing the amplicons themselves. The present invention also relates to a multi-gene panel for ex vivo molecular diagnosis of gastrointestinal stromal tumors and a kit comprising such a panel.

The present invention relates to the technical field of three-dimensional modeling, and particularly to a three-dimensional positioning and surgical navigation system for gastrointestinal stromal tumors with multi-modal image fusion. The system includes: a model initial construction module, which is used to obtain CT images, MRI images and endoscopic images of gastrointestinal stromal tumors, and generate an initial three-dimensional model from multi-layer CT images; a model correction module, which is used to increase the number of triangular meshes in the initial three-dimensional model according to the analysis of the gastrointestinal stromal tumor region in the MRI image to obtain a mesh three-dimensional model; a texture matching module, which is used to determine the best matching pixel corresponding to each triangular mesh in the mesh three-dimensional model, and the best matching pixel belongs to the endoscopic image; a texture rendering module, which is used to perform texture rendering on the mesh three-dimensional model according to the best matching pixel to obtain a three-dimensional positioning model of the gastrointestinal stromal tumor. The present invention combines various types of images to reconstruct a three-dimensional model, improving the detail rendering of the gastrointestinal stromal tumor model.

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.

The invention relates to a YLPM1 protein and application of an accelerant of the YLPM1 protein. Specifically, the invention provides application of the YLPM1 protein and an accelerant thereof in preparation of a preparation or a pharmaceutical composition, and the preparation or the pharmaceutical composition is used for inhibiting growth and metastasis of gastrointestinal stromal tumor cells and promoting apoptosis of the gastrointestinal stromal tumor cells. The invention also provides application of the YLPM1 detection reagent and the YLPM1 knockout reagent, and a method for screening a potential therapeutic agent for treating gastrointestinal stromal tumor.

Disclosed are methods of treatment and inhibitors for gastrointestinal stromal tumor (GIST) in a subject, with an active agent that inhibits a Menin or a member of the Menin-MLL complex.

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and / or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

The invention discloses an application of PHF23 acetylation in gastrointestinal stromal tumor. The research shows that the K211 site acetylation of the PHF23 protein is obviously increased in gastrointestinal stromal tumors with medium and high recurrence risks, and a gastrointestinal stromal tumor diagnosis product taking the PHF23 as a marker and a drug screening method are provided. A cell function test verifies that PHF23 has an inhibiting effect on proliferation and migration of gastrointestinal stromal tumor cells, and the application of the PHF23 acetylation inhibitor as a gastrointestinal stromal tumor treatment medicine is provided.

This invention relates to the crystal form of Bezuclastinib and its preparation method, pharmaceutical compositions containing the crystal form, and the use of the crystal form in the preparation of drugs that inhibit KIT D816V mutations and drugs for treating gastrointestinal stromal tumors and progressive systemic mastocytosis.

This article provides a method for treating individuals with KIT-positive cancers such as gastrointestinal stromal tumors (GIST) and melanomas, wherein the method involves administering a menin inhibitor, optionally in combination with a KIT inhibitor, to the individual.

The invention relates to the technical field of image data processing, in particular to a CT image feature extraction method for gastrointestinal stromal tumor risk stratification, which comprises the following steps of: firstly, acquiring an abdominal CT plane scanning period image and a venous period image of a gastrointestinal stromal tumor patient, and performing coarse segmentation by utilizing gray scale difference of the two periods to obtain a tumor suspected area; a suspected content area is identified by analyzing gray change characteristics of the edge of the area, whether the suspected content area is a real gastrointestinal tract content (such as a contrast agent or bubbles) is further verified, the confirmed content is removed, a pure gastrointestinal stromal tumor area is finally obtained, and radiomics characteristics for risk stratification are extracted from the pure gastrointestinal stromal tumor area. According to the scheme, interference of gastrointestinal tract contents on tumor boundary judgment and internal texture analysis is effectively eliminated, so that the segmentation result is more accurate, high-quality data is provided for image omics feature extraction, the accuracy and reliability of risk layering are enhanced, and preoperative noninvasive accurate evaluation is realized.

The invention belongs to the technical field of organoid culture, and particularly relates to a culture medium for gastrointestinal stromal tumor organoids and a culture method of the culture medium. The invention focuses on the tumor microenvironment, and systematically screens the growth factor and the corresponding receptor which are highly expressed in the tumor cells and the microenvironment thereof through deep analysis of GIST single cell sequencing data. Through rigorous screening and identification processes, it is finally determined that four growth factors of CTGF, IGF2, PDGF-BB and SCF and corresponding receptors of the four growth factors show significant high expression in GIST tumors. Experiments prove that when four key growth factors, namely CTGF, IGF2, PDGF-BB and SCF, are simultaneously added into a GIST organoid culture system, a remarkable synergistic effect exists among the growth factors, and the growth activity of GIST tumor cells is remarkably improved, so that in-vitro continuous proliferation of the GIST tumor cells is promoted, and the culture success rate of the GIST organoid is remarkably improved.

The invention relates to a capture probe group, a kit and a detection method for detecting genetic susceptibility related gene variation of gastrointestinal stromal tumor. The kit comprises a capture probe group for detecting gastrointestinal stromal tumor genetic susceptibility related gene variation conditions and a corresponding reagent based on a next-generation sequencing technology. On the basis of a next-generation sequencing technology, variation conditions of genetic susceptibility related genes NF1, SDHA, SDHB, SDHC and SDHD of the gastrointestinal stromal tumor can be detected at one time by utilizing a hybrid capture method. The capture probe used in the invention has wide coverage and high sequencing depth, and can detect the embryonic line variation of all exon regions of the designed gene. A variant gene library is obtained according to a capture probe, gene variation sites are obtained through sequencing and comparison to a reference genome, all related diseases of gastrointestinal stromal tumor genetic susceptibility related genes can be reported according to databases such as existing literatures and guidelines, pathogenicity of variation and the like, and genetic modes corresponding to the diseases are provided.

To provide a novel method for treating PDGFR kinase-mediated tumors such as gastrointestinal stromal tumors and glioblastoma.SOLUTION: A method for treating or preventing tumor growth or tumor progression mediated by PDGFR kinases, comprises administering to a patient in need thereof an effective amount of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: Figure 1A

The invention discloses a gastrointestinal stromal tumor segmentation method and device and a medium, and is applied to the technical field of medical image.The method comprises the steps that a stomach ultrasound image is obtained, and the stomach ultrasound image comprises a gastrointestinal stromal tumor area; inputting the stomach ultrasound image into a pre-trained segmentation model to obtain a contour map of a gastrointestinal stromal tumor region; in the segmentation model, spatial domain feature extraction is carried out on the stomach ultrasound image through a spatial domain processing module, and low-level features and spatial features are obtained; performing frequency domain feature extraction based on the spatial features through a frequency domain processing module to obtain frequency domain features; fusing the spatial features and the frequency domain features through a fusion module to obtain fused features; and performing segmentation processing through an output module according to the low-level features and the fusion features to obtain a contour map of the gastrointestinal stromal tumor region. According to the method, the segmentation precision of the gastrointestinal stromal tumor can be effectively improved.

The present invention provides a compound of Formula I, a salt thereof, or a solvate thereof, as described herein, the composition is used for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative diseases, colorectal cancer, medulloblastoma, kidney cancer, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous carcinoma, gastrointestinal stromal tumor, glioma, mucus fibrosarcoma, smooth muscle sarcoma, neuroblastoma, synovial sarcoma, mesothelioma, and the like. Gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer and neurological cancer.

The application provides a gastrointestinal stromal tumor patient diagnosis and treatment method and device based on multiple agents, the method comprising: acquiring multi-modal patient data, and acquiring a multi-modal base model based on the multi-modal patient data; performing supervised fine-tuning on the multi-modal base model, and performing reinforcement alignment using a preset group relative strategy optimization algorithm to obtain a multi-modal base model after two-stage reasoning capability training; and generating a standardized reasoning result based on the trained multi-modal base model. According to the application, the perceived multi-modal base model is trained for two-stage reasoning capability, and the multi-modal base model is used to generate a reasoning result, so that the perception task is no longer isolated, and perception, reasoning and tracking diagnosis and treatment are integrated into a unified process. In addition, longitudinal decision training is realized, the comprehensiveness of decision training is improved, and the accuracy of reasoning is improved.

1. The name of this design product: Epithelial-stromal tumor sampler. 2. Purpose of this design product: The needle part can be quickly fixed and replaced by setting a quick-release structure. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The application belongs to the field of medicine, and particularly relates to a novel quinoline compound containing 6-oxo-1-substituted phenyl-1,6-dihydropyridazine-3-carboxamide and application thereof. The novel quinoline compound containing 6-oxo-1-substituted phenyl-1,6-dihydropyridazine-3-carboxamide has a structure of general formula (I). The application also relates to the compound of general formula (I) having a strong inhibitory effect on c-Met kinase, and further relates to the use of the compound and a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and / or preventing a disease caused by abnormally high expression of c-Met kinase, in particular, in the preparation of a drug for treating and / or preventing cancer. The compound of the application is particularly suitable for preparing a drug for treating and / or preventing gastric cancer, colon cancer, lung cancer, gastrointestinal stromal tumor and imatinib-resistant human gastrointestinal stromal tumor.

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and / or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFRα and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRα. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

The present application relates to the field of biological medicine, in particular to the application of RNF128 gene in the prognosis of gastrointestinal stromal tumor (GIST). The present application provides the application of a reagent for detecting the expression amount of RNF128 gene in the preparation of a detection product for the prognosis of GIST. In the present application, the RNF128 gene is highly expressed in low-risk GIST patients and lowly expressed in high-risk GIST patients. The present application takes RNF128 gene as the core, comprehensively covers the key links of GIST treatment and transformation research, and has innovation, science and practicability. The advantages not only lie in the basic research value, but also provide an operable solution for clinical practice, which will significantly improve the diagnosis and treatment effect and the life quality of GIST patients.

The invention relates to the technical field of tumor treatment, in particular to a VEGFR-2 / BRD4 double-target inhibitor and application thereof. The structural general formula of the VEGFR-2 / BRD4 double-target inhibitor is as shown in a formula I in the specification. The tetrahydropteridine compound containing the aryl amide or aryl urea structure, disclosed by the invention, has relatively strong inhibitory activity on VEGFR-2 / BRD4 activity; according to the present invention, the VEGFR-2 / BRD4 double-target inhibitor has good anti-proliferative activity on tumor cells, the compound I-5 shows the optimal activity, and the activity is far superior to the positive control Sorafenib, ReGrafenib and JQ-1, the effect of the ReGrafenib and the effect of the combination of the Sorafenib and the JQ-1 respectively, and the target treatment drug for leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like can be prepared, and the compound I-5 can be used for the preparation of the target treatment drug for treating leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like.

The present invention relates to crystalline avapritinib, polymorphs and hydrates thereof as well as to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising crystalline avapritinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of patients with gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL).

This invention relates to the field of medical image artificial intelligence analysis technology, specifically to an automated preoperative precise risk stratification system and method for gastrointestinal stromal tumors. It includes: a data preprocessing module for acquiring the original sequences of multi-phase computed tomography (CT) scans of the patient's abdomen, and performing three-dimensional volume data construction, spatial dimension standardization, and voxel intensity normalization to generate a standardized three-dimensional tensor; a deep learning model module for receiving the three-dimensional tensor and, based on a 3D Swin Transformer architecture, outputting classification probabilities corresponding to four risk levels: very low risk, low risk, intermediate risk, and high risk; and an interpretable visualization module for generating heatmaps identifying key decision-making regions of the model using gradient-weighted class activation mapping technology, and overlaying these heatmaps back onto the original CT images for visualization.

The application discloses a gastrointestinal stromal tumor organoid culture solution and a use method and application thereof, and belongs to the technical field of gastrointestinal stromal tumor organoid culture. The gastrointestinal stromal tumor organoid obtained by using the culture solution and the culture method provided by the application can retain the histological characteristics and genetic heterogeneity of the original tumor of a patient, can be used as a drug screening model and a disease research model for gastrointestinal stromal tumor treatment, and can promote the progress and development of precise tumor medicine; the gastrointestinal stromal tumor organoid obtained by culture has a high proliferation speed, a high cell survival rate, can be long-term subcultured and amplified, and a gastrointestinal stromal tumor organoid with a diameter of more than 100 microns and good activity can be obtained in 8-10 days; the culture solution is also suitable for culturing wild-type gastrointestinal stromal tumors such as SDH-deficient gastrointestinal stromal tumors; the culture solution does not contain serum and other components with unclear compositions, is not affected by different batches, can maintain a high uniformity in the culture process, can be used for culturing gastrointestinal stromal tumor organoids derived from tumor tissues or malignant cell lines of patients, and is suitable for drug sensitivity detection.